President Trump has signed an executive order aimed at accelerating the review process for psychedelic drugs, including substances like ibogaine, to promote research into their potential medical applications. This directive is intended to reduce regulatory barriers and encourage scientific studies exploring how these compounds might be used to treat mental health conditions.
The announcement was reported by NBC News, highlighting the government's move to facilitate faster evaluation and potential development of psychedelic therapies. This step reflects growing interest in alternative treatments for mental health issues and seeks to support innovation by allowing researchers more freedom to investigate these substances under less restrictive conditions.